{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T20:41:47Z","timestamp":1699562507936},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Cardio Med"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1007\/s11936-000-0016-z","type":"journal-article","created":{"date-parts":[[2007,6,3]],"date-time":"2007-06-03T06:14:18Z","timestamp":1180851258000},"page":"219-226","source":"Crossref","is-referenced-by-count":10,"title":["Raynaud\u2019s phenomenon"],"prefix":"10.1007","volume":"2","author":[{"given":"Jay D.","family":"Coffman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"16_CR1","volume-title":"Raynaud\u2019s Phenomenon","author":"JD Coffman","year":"1989","unstructured":"Coffman JD: Raynaud\u2019s Phenomenon. New York: Oxford University Press; 1989. A comprehensive review of the etiology, clinical picture, diagnosis, and treatment of Raynaud\u2019s phenomenon."},{"key":"16_CR2","first-page":"70","volume":"20","author":"HR Maricq","year":"1993","unstructured":"Maricq HR, Carpentier PH, Weinrich MC, et al.: Geographic variation in the prevalence of Raynaud\u2019s phenomenon\u2014Charleston, SC, USA vs Tarentaise, Savoie, France. J Rheumatol 1993, 20:70\u201376. A possible future classic documenting the varying prevalence of Raynaud\u2019s phenomenon according to climate.","journal-title":"J Rheumatol"},{"key":"16_CR3","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1161\/01.CIR.16.6.1012","volume":"16","author":"RW Gifford Jr","year":"1957","unstructured":"Gifford RW Jr, Hines EA Jr: Raynaud\u2019s disease among women and girls. Circulation 1957, 16:1012\u20131021.","journal-title":"Circulation"},{"key":"16_CR4","first-page":"7","volume":"15","author":"T Lewis","year":"1929","unstructured":"Lewis T: Experiments relating to the peripheral mechanism involved in spasmodic arrest of the circulation in the fingers, a variety of Raynaud\u2019s disease. Heart 1929, 15:7\u2013101.","journal-title":"Heart"},{"key":"16_CR5","first-page":"100","volume":"2","author":"JD Coffman","year":"1990","unstructured":"Coffman JD, Cohen RA: a aa a 2 -Adrenergic and 5-HT2 receptor hypersensitivity in Raynaud\u2019s phenomenon. J Vasc Med Biol 1990, 2:100\u2013105.","journal-title":"J Vasc Med Biol"},{"key":"16_CR6","doi-asserted-by":"crossref","first-page":"682","DOI":"10.2165\/00003495-199652050-00006","volume":"52","author":"JJF Belch","year":"1996","unstructured":"Belch JJF, Meilien H: Pharmacotherapy of Raynaud\u2019s phenomenon. Drugs 1996, 52:682\u2013695. A short, good review of Raynaud\u2019s phenomenon and its treatment.","journal-title":"Drugs"},{"key":"16_CR7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1056\/NEJM198304143081507","volume":"308","author":"RJ Rodeheffer","year":"1983","unstructured":"Rodeheffer RJ, Rommer JA, Wigley F, et al.: Controlled double-blind trial of nifedipine in the treatment of Raynaud\u2019s phenomenon. N Engl J Med 1983, 308:880\u2013883. A well-planned and careful study of the value of nifedipine in Raynaud\u2019s phenomenon.","journal-title":"N Engl J Med"},{"key":"16_CR8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/BF00558230","volume":"37","author":"JF Schmidt","year":"1989","unstructured":"Schmidt JF, Valentin N, Nielsen SL: The clinical effect of felodipine and nifedipine in Raynaud\u2019s phenomenon. Eur J Clin Pharmacol 1989, 37:191\u2013192.","journal-title":"Eur J Clin Pharmacol"},{"key":"16_CR9","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/BF00315217","volume":"40","author":"CGM Kallenberg","year":"1991","unstructured":"Kallenberg CGM, Wouda AA, Meens L, et al.: Once daily felodipine in patients with primary Raynaud\u2019s phenomenon. Eur J Clin Pharmacol 1991, 40:313\u2013315.","journal-title":"Eur J Clin Pharmacol"},{"key":"16_CR10","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/BF01858110","volume":"3","author":"J Leppert","year":"1989","unstructured":"Leppert J, Jonasson T, Nilsson H, et al.: The effect of isradipine, a new calcium-channel antagonist in patients with primary Raynaud\u2019s phenomenon: a single-blind dose-response study. Cardiovasc Drug Ther 1989, 3:397\u2013401.","journal-title":"Cardiovasc Drug Ther"},{"key":"16_CR11","first-page":"858","volume":"14","author":"JT DaCosta","year":"1987","unstructured":"DaCosta JT, Gomes JAM, Santo JE, et al.: Inefficacy of diltiazem in the treatment of Raynaud\u2019s phenomenon with associated connective tissue disease: a double blind placebo controlled study. J Rheumatol 1987, 14:858\u2013859.","journal-title":"J Rheumatol"},{"key":"16_CR12","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00610065","volume":"24","author":"SL Nielsen","year":"1983","unstructured":"Nielsen SL, Vithing K, Rasmussen K: Prazosin treatment of primary Raynaud\u2019s phenomenon. Eur J Clin Pharma-col 1983, 24:421\u2013423. A well-planned study and evaluation of the effect of a 1 -adrenoreceptor blockade in Raynaud\u2019s phenomenon.","journal-title":"Eur J Clin Pharma-col"},{"key":"16_CR13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1056\/NEJM197107292850505","volume":"285","author":"JD Coffman","year":"1971","unstructured":"Coffman JD, Cohen AS: Total and capillary blood flow in Raynaud\u2019s phenomenon. N Engl J Med 1971, 285:259\u2013263.","journal-title":"N Engl J Med"},{"key":"16_CR14","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1172\/JCI106565","volume":"50","author":"EC LeRoy","year":"1971","unstructured":"LeRoy EC, Downey JA, Cannon PJ: Skin capillary blood flow in scleroderma. J Clin Invest 1971, 50:930\u2013939.","journal-title":"J Clin Invest"},{"key":"16_CR15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0140-6736(82)90215-X","volume":"1","author":"AG Franks Jr","year":"1982","unstructured":"Franks AG Jr: Topical glyceryl trinitrate as adjunctive treatment in Raynaud\u2019s disease. Lancet 1982, 1:76\u201377.","journal-title":"Lancet"},{"key":"16_CR16","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/bmj.1.5440.962","volume":"1","author":"ENM Johnston","year":"1965","unstructured":"Johnston ENM, Summerly R, Birnstingl M: Prognosis in Raynaud\u2019s phenomenon after sympathectomy. Br Med J 1965, 1:962\u2013964.","journal-title":"Br Med J"},{"key":"16_CR17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0002-9610(85)90024-8","volume":"150","author":"KA Janoff","year":"1985","unstructured":"Janoff KA, Phinney ES, Porter JM: Lumbar sympathec-tomy for lower extremity vasospasm. Am J Surg 1985, 150:147\u2013152.","journal-title":"Am J Surg"},{"key":"16_CR18","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0266-7681(05)80272-4","volume":"17B","author":"BM O\u2019Brien","year":"1992","unstructured":"O\u2019Brien BM, Kumar PAV, Mellow CG, Oliver TV: Radical microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma. J Hand Surg [Br] 1992, 17B:447\u2013452.","journal-title":"J Hand Surg [Br]"},{"key":"16_CR19","first-page":"953","volume":"12","author":"JB Jobe","year":"1985","unstructured":"Jobe JB, Beetham WP, Roberta DE, et al.: Induced vasodilation as a home treatment for Raynaud\u2019s disease. J Rheumatol 1985, 12:953\u2013956. Demonstrates that a simple nondrug treatment may improve Raynaud\u2019s phenomenon in many patients.","journal-title":"J Rheumatol"},{"key":"16_CR20","first-page":"90","volume":"12","author":"DE Yocum","year":"1985","unstructured":"Yocum DE, Hoden R, Sundstrom CR, et al.: Use of biofeedback training in treatment of Raynaud\u2019s disease and phenomenon. J Rheumatol 1985, 12:90\u201393.","journal-title":"J Rheumatol"},{"key":"16_CR21","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/bmj.298.6673.561","volume":"298","author":"M Rademaker","year":"1989","unstructured":"Rademaker M, Cooke ED, Almond NE, et al.: Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud\u2019s phenomenon in patients with systemic sclerosis: a double blind randomized study. Br Med J 1989, 298:561\u2013564.","journal-title":"Br Med J"},{"key":"16_CR22","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.44.11.754","volume":"44","author":"JS Mohrland","year":"1985","unstructured":"Mohrland JS, Porter JM, Smith EA, et al.: A multicenter, placebo-controlled, double-blind study of prostaglan-din E1 in Raynaud\u2019s syndrome. Ann Rheum Dis 1985, 44:754\u2013760.","journal-title":"Ann Rheum Dis"},{"key":"16_CR23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.2165\/00003495-199448060-00003","volume":"48","author":"VF Challenor","year":"1994","unstructured":"Challenor VF: Angiotensin converting enzyme inhibitors in Raynaud\u2019s phenomenon. Drugs 1994, 48:864\u2013867.","journal-title":"Drugs"},{"key":"16_CR24","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1046\/j.1365-2796.1997.00219.x","volume":"242","author":"P Pancera","year":"1997","unstructured":"Pancera P, Sansone S, Secchi S, et al.: The effects of thromboxane inhibition (picotamide) and angio-tensin II receptor blockade (losartan) in primary Raynaud\u2019s phenomenon. J Intern Med 1997, 242:373\u2013376.","journal-title":"J Intern Med"}],"container-title":["Current Treatment Options in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-000-0016-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11936-000-0016-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11936-000-0016-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:52:25Z","timestamp":1559436745000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11936-000-0016-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["16"],"URL":"https:\/\/doi.org\/10.1007\/s11936-000-0016-z","relation":{},"ISSN":["1092-8464","1534-3189"],"issn-type":[{"value":"1092-8464","type":"print"},{"value":"1534-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}